Clinical Trial Update: Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury [Phase 2]

View source ↗

Summary

Phase 2 compassionate-use trial of Omegaven for parenteral nutrition–induced hepatic injury has been terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Injury

Drugs mentioned

• Omegaven (fish oil-based intravenous fat emulsion)

Snippet

Sponsor: Midwestern Regional Medical Center | Conditions: Cancer, Hepatic Injury | Phase 2 | Status: TERMINATED | Results posted: 2018-06-27